Titre : | A randomized controlled trial of pemoline for attention-deficit/hyperactivity disorder in substance-abusing adolescents |
Titre traduit : | (Une étude contrôlée randomisée sur l'usage de la pémoline pour les troubles de l'attention avec hyperactivité chez les adolescents qui abusent de substances) |
Auteurs : | RIGGS P. D. ; S. K. HALL ; S. K. MIKULICH-GILBERTSON ; LOHMAN M. ; KAYSER A. |
Type de document : | Périodique |
Année de publication : | 2004 |
Format : | 420-429 |
Note générale : |
Journal of the American Academy of Child and Adolescent Psychiatry, 2004, 43, (4), 420-429 |
Langues: | Français |
Mots-clés : |
Thésaurus mots-clés ADOLESCENT ; TROUBLES DE L'ATTENTION ; ABUS ; TROUBLES DU COMPORTEMENT ; COMORBIDITE ; STIMULANTS ; PHARMACOTHERAPIE ; ESSAI THERAPEUTIQUEThésaurus géographique ETATS-UNIS |
Résumé : |
ENGLISH : OBJECTIVE: In adolescents with substance use disorder (SUD), comorbid attention-deficit/hyperactivity disorder (ADHD) is associated with greater severity of substance abuse, conduct problems, and worse treatment outcomes. Although many controlled trials have established the efficacy of psychostimulants, including pemoline, for ADHD in children and adolescents, none have been conducted in adolescents with SUD. This randomized, placebo-controlled trial, conducted between 1996 and 2000, evaluated the safety and efficacy of pemoline on substance abuse and conduct problems. METHOD: Sixty-nine adolescents (aged 13-19) with conduct disorder (CD), SUD, and ADHD were recruited from the community and randomly assigned to a 12-week clinical trial of pemoline (n = 35) or placebo (n = 34), titrated over 4 weeks to a single morning dose of 75 to 112.5 mg as tolerated. RESULTS: Pemoline had greater efficacy than placebo for ADHD as determined by significantly more Clinician's Global Impression-Improvement (CGI-I) ratings of 1 (very much improved) or 2 (much improved) at the study endpoint (n = 69; p <.05 there was also greater reduction in adhd severity on the parent-rated conners hyperactivity-impulsivity scale pemoline-treated study completers compared to placebo-treated n="17;" placebo p but no difference between groups intent-to-treat analysis substance use did not decline either group and baseline endpoint change or cd symptoms. overall pemoline well tolerated demonstrating a good safety profile elevation liver enzyme levels. conclusions: efficacious for have an impact abuse absence of specific treatment sud.> |
Domaine : | Plusieurs produits / Several products |
Affiliation : |
Department of Psychiatry, University of Colorado School of Medicine, Denver 80262 Etats-Unis. United States. |
Numéro Toxibase : | 1301567 |
Centre Emetteur : | 13 OFDT |
Cote : | A01837 |
Exemplaires
Disponibilité |
---|
aucun exemplaire |
Accueil